Use the search bar to search by drug, manufacturer, or indication. You can also filter your search results by drug, manufacturer, or negotiation status.
To learn more about a specific file, click on a drug name. It will open its product card, which includes information about the manufacturer, indication (the approved use of a drug by Health Canada), and negotiation milestones.
There are 6 negotiation statuses, which reflect where the drug file is in the pCPA process:
Under consideration for negotiation
We’re considering the evidence and gathering other information to inform the negotiation approach, including eligibility for expedited negotiation pathways.
Active negotiation
Negotiation activities are underway for the drug, with our negotiation team and the manufacturer meeting regularly.
Concluded with an LOI
Negotiations ended successfully with mutually agreed-upon terms, and these terms are outlined in a letter of intent (LOI).
Concluded without agreement
Negotiating parties couldn’t agree on terms. Negotiations have ended without a pricing agreement for the drug.
Negotiation not pursued
It has been decided, in partnership with our member drug plans, not to engage in a negotiation. Typically, this is because the drug’s health technology (HTA) assessment reimbursement recommendations were negative, or “do not reimburse.” Other reasons, like the manufacturer declining to negotiate or a lack of supply of the drug in Canada, may be reflected in an accompanying status note.
Negotiation on hold
We began negotiation activities for the drug, but they’ve since been paused. An accompanying status note indicates whether the pause was requested by the manufacturer or the pCPA.
Learn more
To learn more about our negotiation processes, or where the pCPA fits into the Canadian drug reimbursement system, consult these pages:
Status:
Under consideration for negotiation
Manufacturer:
Hoffmann-La Roche Ltd.
Indication:
As monotherapy for the treatment of adult patients with relapsed or refractory follicular lymphoma (Grades 1 – 3a) who have received at least two prior lines of systemic therapy.
Last updated:
July 28, 2026
Status:
Negotiations were not pursued
Manufacturer:
Novartis Pharmaceuticals Canada Inc.
Indication:
For the treatment of adult patients with Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase (CP) who have previously received 1 tyrosine kinase inhibitor (second line).
Last updated:
July 28, 2026
Status:
Active negotiation
Manufacturer:
Incyte Biosciences Canada Corporation
Indication:
in combination with rituximab and lenalidomide for the treatment of adult patients with grade 1, 2, or 3a relapsed or refractory follicular lymphoma.
Last updated:
July 27, 2026
Jatenzo (testosterone undecanoate)
Status:
Active negotiation
Manufacturer:
Tolmar International
Indication:
Testosterone replacement therapy
Last updated:
July 27, 2026
Status:
Under consideration for negotiation
Manufacturer:
Sanofi-Aventis Canada Inc.
Indication:
For the treatment of adult patients with polymyalgia rheumatica (PMR) who have had an inadequate response to corticosteroids, or who have experienced a relapse during corticosteroid taper.
Last updated:
July 27, 2026
Status:
Concluded with an LOI
Manufacturer:
Pfizer Canada ULC
Indication:
In combination with enzalutamide for the treatment of adult patients with homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC).
Last updated:
July 27, 2026
Status:
Concluded without agreement
Manufacturer:
Pfizer Canada ULC
Indication:
in combination with cetuximab and chemotherapy, for the treatment of patients with metastatic colorectal cancer (mCRC) with a BRAF V600E mutation, as detected by a validated test.
Last updated:
July 24, 2026
Status:
Under consideration for negotiation
Manufacturer:
Knight Therapeutics Inc.
Indication:
for the treatment of plaque psoriasis after the failure of a vitamin D analogue or a medium- or high-potency topical corticosteroid
Last updated:
July 21, 2026
Status:
Active negotiation
Manufacturer:
AstraZeneca Canada Inc.
Indication:
As an add-on maintenance treatment with intranasal corticosteroids in adult patients with severe chronic rhinosinusitis with nasal polyps (CRSwNP) inadequately controlled by systemic corticosteroids and/or surgery
Last updated:
July 21, 2026
Status:
Under consideration for negotiation
Manufacturer:
Medison Pharma Canada Inc.
Indication:
For the treatment of adult patients with indolent systemic mastocytosis (ISM) with moderate to severe symptoms inadequately controlled on symptomatic treatment.
Last updated:
July 20, 2026